Join
Live feed
·
PRReleasevia Quantisnow
Aeglea BioTherapeutics Inc. logo

Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency

ByQuantisnow·Wall Street's wire, on your screen.
AGLE· Aeglea BioTherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AGLE (Aeglea BioTherapeutics Inc.) and more on Quantisnow.